Clora (@MeetClora) header
Clora (@MeetClora) profile picture

The best place to discover, build, and manage on-demand life science teams.

Boston, MA
Joined August 2015
Photo by Clora (@MeetClora)Photo by Clora (@MeetClora)Photo by Clora (@MeetClora)Photo by Clora (@MeetClora)Photo by Clora (@MeetClora)Photo by Clora (@MeetClora)Photo by Clora (@MeetClora)Photo by Clora (@MeetClora)Photo by Clora (@MeetClora)Photo by Clora (@MeetClora)
Congrats to our client @formationbio on its new $600M #DrugDevelopment Accelerator Fund to expand its clinical-stage portfolio. The fund will in-license or acquire Phase 1/2 programs, each housed in its own entity and backed by Formation’s shared development platform.
Today we’re announcing the $600M Formation Bio Drug Development Accelerator Fund. @lintaho and I started @FormationBio because we believed the biggest bottleneck in bringing new medicines to patients wasn’t drug discovery, but drug development. As AI dramatically accelerates discovery, that bottleneck is only becoming more acute. Without the capital and capacity to advance promising drugs through clinical trials, much of that progress won’t translate into medicines for patients. Our new Fund brings together dedicated capital, drug development expertise, and AI-powered development capabilities to acquire promising drugs and advance them through the clinic.
1
55
Big news for our client Rapport Therapeutics: RAP-219 met its Phase 2 primary endpoint in acute #bipolar mania, with statistically significant improvement vs. placebo at Week 3 and favorable tolerability. Phase 3 planned 2H 2027. Congrats, Rapport team! ow.ly/l9sU51006IM
30
Big week for #radiopharma: BMS’s RYZ101, the lead asset from its $4.1B RayzeBio acquisition, hit its Phase 3 primary endpoint, and @GEHealthCare agreed to acquire Sofie Biosciences, a leading U.S. CMO for PET radiopharmaceuticals, for $945M. ow.ly/xv9e50ZXjy3
16
Why do 9 out of 10 drugs that enter the clinic fail? @bmsnews Chief Research Officer Robert @rplenge joins @rahulc on @Biotech2050Pod to discuss human #biology, #AI in #drugdiscovery, and why novel targets matter. His advice: “Hold your why tightly and your how loosely.”
🔬 Can causal human biology change the odds of drug discovery? BMS Chief Research Officer @rplenge joins @rahulc to explore target diversity, immune reset, AI in R&D, blended innovation & the future of transformative medicines. 🎧 - on.soundcloud.com/5z8XpzDC0q… #Biotech2050 #Biotech
22
"Earn the right to grow." On the latest @Biotech2050Pod, @rahulc talks with @KymeraTx CEO @NelloMainolfi about raising capital only after hitting milestones, focusing on #immunology, and why culture matters as much as the #science. Listen to the #podcast now using the link below.
🧬 From a fringe scientific bet to pioneering targeted protein degradation.@KymeraTx CEO @NelloMainolfi joins @rahulc on #Biotech2050 to discuss drug discovery, immunology, disciplined growth & building a culture that can do what’s never been done. 🎧 - on.soundcloud.com/ksNbuIbEJt…
2
99
Frazier Life Sciences just closed $1.1B in new commitments for its public #biotech fund, pushing total assets to roughly $2.8B — signaling continued appetite for small and mid-cap biotech even as the broader funding environment stays selective: ow.ly/fSoQ50ZOgAa
33
The federal government is investing up to $125M to rethink how personalized #RNAmedicines are made. ARPA-H’s GIVE program aims to bring manufacturing faster and closer to patients, highlighting the need for specialized expertise to scale: ow.ly/rxEH50ZLtg4 #Biotech #RNA
31
Biotech is having a real moment. The XBI has climbed from ~$90 to nearly $170 this year. 2026 has already topped 2025's full-year IPO count, and several debuts are trading well above their launch price: ow.ly/Ax0S50ZHrqq #biotech #lifesciences
1
32
Big week for personalized medicine: @moderna_tx & @Merck mRNA cancer vaccine, Intismeran, hit its primary endpoint in a Phase 3 melanoma trial with Keytruda—a major milestone for personalized #cancer #vaccines after years of promise. Congrats to both teams!
Moderna and @Merck today announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with intismeran autogene, a novel investigational mRNA-based individualized neoantigen therapy jointly developed by Merck and Moderna, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with completely resected Stage IIB-IV melanoma. Read more:
61
Congrats to our client @PTCBio on winning the competitive auction for Sangamo’s ST-920, a BLA-stage #genetherapy for Fabry disease. Beating out two other bidders says a lot about conviction. ST-920 could see a potential commercial launch as early as 2027.
PTC Therapeutics was selected as the winning bidder to acquire ST-920 – a BLA-stage one-time administered AAV gene therapy for Fabry disease – from Sangamo Therapeutics in a competitive bankruptcy auction. Learn more: ow.ly/O0ie50Zz6cz
51
What will it take for #AI to truly transform #drugdiscovery? On the latest @Biotech2050Pod, Clora CEO @rahulc speaks with @nick_myerberg of Braidwell about AI-native #biotech, proprietary data, and the future of discovery. Listen using the link below.
AI won't replace scientists - it will redefine drug discovery @rahulc talks w/ @nick_myerberg, Partner & Head of AI @braidwell, on AI-native biotech, proprietary data, autonomous labs & why the next decade could transform how medicines are discovered 🎧 - on.soundcloud.com/cUxDlhSnqD…
4
135
Clora CEO @rahulc talks with Robert Jacks, CEO of @Sparrow_Pharma, about #biotech #leadership, precision medicine & the future of type 2 #diabetes care. Listen to the full #podcast episode now!
From civil engineer to biotech CEO. @rahulc speaks with Robert Jacks, CEO of @Sparrow_Pharma, on building sustainable biotech companies, precision medicine, cortisol biology, & the future of treating difficult-to-control diabetes. 🎧 - on.soundcloud.com/hc4cVoW7qs… #Biotech2050
32
Congratulations to our client @OrcaBio on the U.S. FDA approval of TREGZI™. We're proud to support organizations advancing innovation in #celltherapy and look forward to seeing the impact of this important milestone.
We are proud to announce the U.S. FDA approval of our new ​​precision-engineered cell therapy for allogeneic transplant in people with hematologic malignancies. This marks a significant milestone for Orca Bio, ​​and most importantly, for the patients we serve.  ​​​​​​   Learn more: bit.ly/4vGQOU0 #CellTherapy #BloodCancer
1
34
Biopharma dealmaking is gaining momentum. PwC reports Q1 M&A deal value surpassed $65B—the strongest start since 2020—signaling renewed confidence across the industry. As companies accelerate #innovation, access to specialized #expertise will be critical. ow.ly/HTHi50ZepR0
34
What does it mean to put patients at the center of #biotech? Hear Clora CEO @rahulc talk with @ardelyx CEO Mike Raab & Chief Patient Officer Laura Williams about patient-centric #leadership, resilience, and keeping patients as the North Star through every challenge.
What does patient-centricity look like when embedded in C-suite? @ardelyx CEO Mike Raab & Chief Patient Officer Laura Williams join @rahulc to share lessons on leadership, perseverance, patient advocacy, & navigating the FDA journey. 🧬❤️ 🎧 - on.soundcloud.com/hIb2q3Oa13… #Biotech2050
50
Hear Clora CEO @rahulc speak with @AcadiaPharma CEO Catherine Owen Adams about her journey to #biotech #leadership, the future of CNS #innovation, and the forces shaping biotech today. Listen to the full episode.
How do you go from pharmacist to leading a billion-dollar biotech? Catherine Owen Adams, CEO of @AcadiaPharma, joins @rahulc on #Biotech2050 to discuss neuro & rare disease innovation, commercialization, AI, & first-time CEO lessons. 🧠 🎙️- on.soundcloud.com/nXJ0ArsZaZ…
26
Our new website is live: ow.ly/m7QU50YOvst 15,000+ vetted life sciences consultants. Access in days, not months. Faster than hiring. More flexible than CROs. #Biotech #LifeSciences
21